BRAF and metastatic melanoma: However, BRAF monotherapy is rarely associated with LVD.45 The COLUMBUS trial conducted in BRAF mutant metastatic melanoma patients investigating a combination of encorafenib plus binimetinib/encorafenib/vemurafenib showed a 6% incidence of all-grade, 6% grades 1–2, and 2% grade 3 LVD.46